Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...

A new platform for studying mtDNA mutations implicated in human disease could help accelerate treatments for mitochondrial ...

SAB Biotherapeutics’ SAB-142 targets stage 2/3 type 1 diabetes, aiming to preserve beta-cell function. Click here to read my ...

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...

A layered coating on delignified wood enables solar heat storage and electricity generation without carbonization, while ...

A biodegradable ionic hydrogel battery modeled on electric eel organs powers a nerve conduit that accelerates peripheral nerve regeneration without external energy.

Explore how parenteral manufacturing solutions are evolving for specific drug formulations and meeting the demands of advanced therapies.

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...

Integrating proteomics with systems biology reveals complex cellular networks, improving disease mechanisms understanding and precision medicine applications.

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

Funding received in the initial years after an investigator first establishes their research lab can be pivotal in helping to ...